Similar articles

Abstract: non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer cases. The pathogenesis of NSCLC involves complex gene networks that include different types of non-coding RNAs, such as long non-coding RNAs (lncRNAs). The role of lncRNAs in NSCLC is gaining an increasing interest as their function is being explored in various human cancers. Recently, a new oncogenic lncRNA, LINC00152 (cytoskeleton regulator RNA (CYTOR)), has been identified in different tumor types. In NSCLC, the high expression of LINC00152 in tumor tissue and peripheral blood samples has been shown to be associated with worse prognoses of NSCLC patients. Overexpression of LINC00152 has been confirmed to promote the proliferation, invasion, and migration of NSCLC cells in vitro, as well as increase tumor growth in vivo. This review discusses the role of LINC00152 in NSCLC.

LINC00152在非小细胞肺癌中的作用

[1]Abudayyeh OO, Gootenberg JS, Essletzbichler P, et al., 2017. RNA targeting with CRISPR-Cas13. Nature, 550(7675):280-284.

[2]Arun G, Diermeier SD, Spector DL, 2018. Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med, 24(3):257-277.

[3]Bhan A, Soleimani M, Mandal SS, 2017. Long noncoding RNA and cancer: a new paradigm. Cancer Res, 77(15):3965-3981.

[4]Bian ZH, Zhang JW, Li M, et al., 2017. Long non-coding RNA LINC00152 promotes cell proliferation, metastasis, and confers 5-FU resistance in colorectal cancer by inhibiting miR-139-5p. Oncogenesis, 6(11):395.

[5]Cai JQ, Zhang JW, Wu PF, et al., 2018. Blocking LINC00152 suppresses glioblastoma malignancy by impairing mesenchymal phenotype through the miR-612/AKT2/NF-κB pathway. J Neuro-Oncol, 140(2):225-236.

[6]Cai Q, Wang ZQ, Wang SH, et al., 2016. Upregulation of long non-coding RNA LINC00152 by SP1 contributes to gallbladder cancer cell growth and tumor metastasis via PI3K/AKT pathway. Am J Transl Res, 8(10):4068-4081.

[7]Cai Q, Wang ZQ, Wang SH, et al., 2017. Long non-coding RNA LINC00152 promotes gallbladder cancer metastasis and epithelial-mesenchymal transition by regulating HIF-1α via miR-138. Open Biol, 7(1):160247.

[8]Chen J, Zhang K, Song HZ, et al., 2016. Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells. Oncotarget, 7(38):62474-62489.

[9]Chen MW, Xu XN, Ma HQ, 2019. Identification of oncogenic long noncoding RNAs CASC9 and LINC00152 in oral carcinoma through genome-wide comprehensive analysis. Anti-Cancer Drugs, 30(4):356-362.

[10]Chen PX, Fang XL, Xia B, et al., 2018. Long noncoding RNA LINC00152 promotes cell proliferation through competitively binding endogenous miR-125b with MCL-1 by regulating mitochondrial apoptosis pathways in ovarian cancer. Cancer Med, 7(9):4530-4541.

[11]Chen QN, Chen X, Chen ZY, et al., 2017. Long intergenic non-coding RNA 00152 promotes lung adenocarcinoma proliferation via interacting with EZH2 and repressing IL24 expression. Mol Cancer, 16(1):17.

[12]Chen WM, Huang MD, Sun DP, et al., 2016. Long intergenic non-coding RNA 00152 promotes tumor cell cycle progression by binding to EZH2 and repressing p15 and p21 in gastric cancer. Oncotarget, 7(9):9773-9787.

[13]Chen X, Li DH, Gao Y, et al., 2018. Long intergenic noncoding RNA 00152 promotes glioma cell proliferation and invasion by interacting with miR-16. Cell Physiol Biochem, 46(3):1055-1064.

[14]Choi SW, Kim HW, Nam JW, 2019. The small peptide world in long noncoding RNAs. Brief Bioinf, 20(5):1853-1864.

[15]Collisson EA, Campbell JD, Brooks AN, et al., 2014. Comprehensive molecular profiling of lung adenocarcinoma. Nature, 511(7511):543-550.

[16]Crooke ST, 2017. Molecular mechanisms of antisense oligonucleotides. Nucleic Acid Ther, 27(2):70-77.

[17]Cuadrado A, Nebreda AR, 2010. Mechanisms and functions of p38 MAPK signalling. Biochem J, 429(3):403-417.

[18]Davis CA, Hitz BC, Sloan CA, et al., 2018. The encyclopedia of DNA elements (ENCODE):data portal update. Nucleic Acids Res, 46(D1):D794-D801.

[19]Deng X, Zhao XF, Liang XQ, et al., 2017. Linc00152 promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma. Biomed Pharmacother, 90:100-108.

[20]Dey BK, Mueller AC, Dutta A, 2014. Long non-coding RNAs as emerging regulators of differentiation, development, and disease. Transcription, 5(4):e944014.

[21]El-Deiry WS, 2016. p21(WAF1) mediates cell-cycle inhibition, relevant to cancer suppression and therapy. Cancer Res, 76(18):5189-5191.

[22]Esfandi F, Taheri M, Omrani MD, et al., 2019. Expression of long non-coding RNAs (lncRNAs) has been dysregulated in non-small cell lung cancer tissues. BMC Cancer, 19: 222.

[23]Ettinger DS, Wood D, Akerley W, et al., 2015. Non-small cell lung cancer, version 6.2015. J Natl Compr Canc Netw, 13(5):515-524.

[24]Fatica A, Bozzoni I, 2014. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet, 15(1):7-21.

[25]Feng SM, Zhang J, Su WM, et al., 2017. Overexpression of LINC00152 correlates with poor patient survival and knockdown impairs cell proliferation in lung cancer. Sci Rep, 7(1):2982.

[26]Fidler MM, Bray F, 2018. Global cancer inequalities. Front Oncol, 8:293.

[27]Gong NQ, Teng XC, Li JH, et al., 2019. Antisense oligonucleotide-conjugated nanostructure-targeting lncRNA MALAT1 inhibits cancer metastasis. ACS Appl Mater Interfaces, 11(1):37-42.

[28]Gudenas BL, Wang J, Kuang SZ, et al., 2019. Genomic data mining for functional annotation of human long noncoding RNAs. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 20(6):476-487.

[29]Gutschner T, Hämmerle M, Eißmann M, et al., 2013. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res, 73(3):1180-1189.

[30]Hu HB, Jie HY, Zheng XX, 2016. Three circulating lncRNA predict early progress of esophageal squamous cell carcinoma. Cell Physiol Biochem, 40(1-2):117-125.

[31]Hu XD, Bao JT, Wang Z, et al., 2016. The plasma lncRNA acting as fingerprint in non-small-cell lung cancer. Tumour Biol, 37(3):3497-3504.

[32]Hu XL, Wang J, He W, et al., 2018. Down-regulation of lncRNA Linc00152 suppressed cell viability, invasion, migration, and epithelial to mesenchymal transition, and reversed chemo-resistance in breast cancer cells. Eur Rev Med Pharmacol Sci, 22(10):3074-3084.

[33]Huang Y, Luo H, Li F, et al., 2018. LINC00152 down-regulated miR-193a-3p to enhance MCL1 expression and promote gastric cancer cells proliferation. Biosci Rep, 38(3):BSR20171607.

[34]Ji J, Tang JW, Deng L, et al., 2015. LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway. Oncotarget, 6(40):42813-42824.

[35]Li J, Wang X, Tang J, et al., 2015. HULC and Linc00152 act as novel biomarkers in predicting diagnosis of hepatocellular carcinoma. Cell Physiol Biochem, 37(2):687-696.

[36]Li MH, Ning J, Li ZH, et al., 2018. LINC00152 promotes the growth and invasion of oral squamous cell carcinoma by regulating miR-139-5p. OncoTargets Ther, 11:6295-6304.

[37]Li ND, Feng XB, Tan Q, et al., 2017. Identification of circulating long noncoding RNA Linc00152 as a novel biomarker for diagnosis and monitoring of non-small-cell lung cancer. Disease markers, 2017:7439698.

[38]Li QE, Shao YF, Zhang XJ, et al., 2015. Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer. Tumor Biol, 36(3):2007-2012.

[39]Li SH, Wen DC, Che ST, et al., 2018. Knockdown of long noncoding RNA 00152 (LINC00152) inhibits human retinoblastoma progression. OncoTargets Ther, 11:3215-3223.

[40]Liu DL, Gao M, Wu K, et al., 2019. LINC00152 facilitates tumorigenesis in esophageal squamous cell carcinoma via miR-153-3p/FYN axis. Biomed Pharmacother, 112:108654.

[41]Liu J, Wan L, Lu KH, et al., 2015. The long noncoding RNA MEG3 contributes to cisplatin resistance of human lung adenocarcinoma. PLoS ONE, 10(5):e0114586.

[42]Liu XZ, Yidayitula Y, Zhao H, et al., 2018. LncRNA LINC00152 promoted glioblastoma progression through targeting the miR-107 expression. Environ Sci Pollut Res, 25(18):17674-17681.

[43]Liu ZL, Sun M, Lu KH, et al., 2013. The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21^WAF1/CIP1 expression. PLoS ONE, 8(10):e77293.

[44]Liu ZZ, Liu AF, Nan A, et al., 2019. The linc00152 controls cell cycle progression by regulating CCND1 in 16HBE cells malignantly transformed by cigarette smoke extract. Toxicol Sci, 167(2):496-508.

[45]Ma P, Zhang ML, Nie FQ, et al., 2017. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer. Biomed Pharmacother, 87:20-26.

[46]Ma P, Wang HT, Sun JY, et al., 2018. LINC00152 promotes cell cycle progression in hepatocellular carcinoma via miR-193a/b-3p/CCND1 axis. Cell Cycle, 17(8):974-984.

[47]Mao Y, Tie Y, Du J, et al., 2019. LINC00152 promotes the proliferation of gastric cancer cells by regulating B-cell lymphoma-2. J Cell Biochem, 120(3):3747-3756.

[48]Nishizawa Y, Konno M, Asai A, et al., 2018. Hypoxia stimulates the cytoplasmic localization of oncogenic long noncoding RNA LINC00152 in colorectal cancer. Int J Oncol, 52(2):453-460.

[49]Nötzold L, Frank L, Gandhi M, et al., 2017. The long non-coding RNA LINC00152 is essential for cell cycle progression through mitosis in HeLa cells. Sci Rep, 7(1):2265.

[50]Orom UA, Derrien T, Beringer M, et al., 2010. Long noncoding RNAs with enhancer-like function in human cells. Cell, 143(1):46-58.

[51]Peng WX, Koirala P, Mo YY, 2017. LncRNA-mediated regulation of cell signaling in cancer. Oncogene, 36(41):5661-5667.

[52]Qiu JJ, Yan JB, 2015. Long non-coding RNA LINC01296 is a potential prognostic biomarker in patients with colorectal cancer. Tumor Biol, 36(9):7175-7183.

[53]Rapisuwon S, Vietsch EE, Wellstein A, 2016. Circulating biomarkers to monitor cancer progression and treatment. Comput Struct Biotechnol J, 14:211-222.

[54]Reon BJ, Karia BTR, Kiran M, et al., 2018. LINC00152 promotes invasion through a 3'-hairpin structure and associates with prognosis in glioblastoma. Mol Cancer Res, 16(10):1470-1482.

[55]Seo JS, Ju YS, Lee WC, et al., 2012. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res, 22(11):2109-2119.

[56]Shen X, Zhong JX, Yu P, et al., 2019. YY1-regulated LINC00152 promotes triple negative breast cancer progression by affecting on stability of PTEN protein. Biochem Biophys Res Commun, 509(2):448-454.

[57]Su M, Xiao YH, Tang JM, et al., 2018. Role of lncRNA and EZH2 interaction/regulatory network in lung cancer. J Cancer, 9(22):4156-4165.

[58]Sun ZH, Guo X, Zang MC, et al., 2019. Long non-coding RNA LINC00152 promotes cell growth and invasion of papillary thyroid carcinoma by regulating the miR-497/BDNF axis. J Cell Physiol, 234(2):1336-1345.

[59]Teng W, Qiu CG, He ZH, et al., 2017. Linc00152 suppresses apoptosis and promotes migration by sponging miR-4767 in vascular endothelial cells. Oncotarget, 8(49):85014-85023.

[60]Torre LA, Siegel RL, Jemal A, 2016. Lung cancer statistics. In: Ahmad A, Gadgeel S (Eds.), Lung Cancer and Personalized Medicine: Current Knowledge and Therapies. Springer, Cham, p.1-19.

[61]Vester B, Wengel J, 2004. LNA (locked nucleic acid):  high-affinity targeting of complementary RNA and DNA. Biochemistry, 43(42):13233-13241.

[62]Wang HF, Chen WX, Yang P, et al., 2019. Knockdown of linc00152 inhibits the progression of gastric cancer by regulating microRNA-193b-3p/ETS1 axis. Cancer Biol Ther, 20(4):461-473.

[63]Wang W, Wu F, Zhao Z, et al., 2018. Long noncoding RNA LINC00152 is a potential prognostic biomarker in patients with high-grade glioma. CNS Neurosci Ther, 24(10):957-966.

[64]Wang X, Yu HF, Sun WJ, et al., 2018. The long non-coding RNA CYTOR drives colorectal cancer progression by interacting with NCL and Sam68. Mol Cancer, 17(1):110.

[65]Wang Y, Zhou J, Xu YJ, et al., 2018. Long non-coding RNA LINC00968 acts as oncogene in NSCLC by activating the Wnt signaling pathway. J Cell Physiol, 233(4):3397-3406.

[66]Wang YJ, Liu JZ, Bai HZ, et al., 2017. Long intergenic non-coding RNA 00152 promotes renal cell carcinoma progression by epigenetically suppressing P16 and negatively regulates miR-205. Am J Cancer Res, 7(2):312-322.

[67]Wang YL, Li MM, Dong CX, et al., 2019. Linc00152 knockdown inactivates the Akt/mTOR and Notch1 pathways to exert its anti-hemangioma effect. Life Sci, 223:22-28.

[68]Wu JL, Shuang ZY, Zhao JF, et al., 2018. Linc00152 promotes tumorigenesis by regulating DNMTs in triple-negative breast cancer. Biomed Pharmacother, 97:1275-1281.

[69]Wu Y, Tan C, Weng WW, et al., 2016. Long non-coding RNA Linc00152 is a positive prognostic factor for and demonstrates malignant biological behavior in clear cell renal cell carcinoma. Am J Cancer Res, 6(2):285-299.

[70]Xie YJ, Zhang Y, Du LT, et al., 2018. Circulating long noncoding RNA act as potential novel biomarkers for diagnosis and prognosis of non-small cell lung cancer. Mol Oncol, 12(5):648-658.

[71]Xu SP, Wan L, Yin HZ, et al., 2017. Long noncoding RNA Linc00152 functions as a tumor propellant in pan-cancer. Cell Physiol Biochem, 44(6):2476-2490.

[72]Yang T, Zeng HM, Chen WQ, et al., 2016. Helicobacter pylori infection, H19 and LINC00152 expression in serum and risk of gastric cancer in a Chinese population. Cancer Epidemiol, 44:147-153.

[73]Yu JJ, Liu Y, Guo C, et al., 2017. Upregulated long non-coding RNA LINC00152 expression is associated with progression and poor prognosis of tongue squamous cell carcinoma. J Cancer, 8(4):523-530.

[74]Yu MJ, Xue YX, Zheng J, et al., 2017. Linc00152 promotes malignant progression of glioma stem cells by regulating miR-103a-3p/FEZF1/CDC25A pathway. Mol Cancer, 16(1):110.

[75]Yu TH, Xu ZH, Zhang XH, et al., 2018. Long intergenic non-protein coding RNA 152 promotes multiple myeloma progression by negatively regulating microRNA-497. Oncol Rep, 40(6):3763-3771.

[76]Yu Y, Yang J, Li QP, et al., 2017. LINC00152: a pivotal oncogenic long non-coding RNA in human cancers. Cell Prolif, 50(4):e12349.

[77]Yue B, Cai DL, Liu CC, et al., 2016. Linc00152 functions as a competing endogenous RNA to confer oxaliplatin resistance and holds prognostic values in colon cancer. Mol Ther, 24(12):2064-2077.

[78]Yue B, Liu CC, Sun HM, et al., 2018. A positive feed-forward loop between lncRNA-CYTOR and Wnt/β-catenin signaling promotes metastasis of colon cancer. Mol Ther, 26(5):1287-1298.

[79]Zhang J, Li WQ, 2018. Long noncoding RNA CYTOR sponges miR-195 to modulate proliferation, migration, invasion and radiosensitivity in nonsmall cell lung cancer cells. Biosci Rep, 38(6):BSR20181599.

[80]Zhang PP, Wang YQ, Weng WW, et al., 2017. Linc00152 promotes cancer cell proliferation and invasion and predicts poor prognosis in lung adenocarcinoma. J Cancer, 8(11):2042-2050.

[81]Zhang XX, Tao WG, 2019. Long noncoding RNA LINC00152 facilitates the leukemogenesis of acute myeloid leukemia by promoting CDK9 through miR-193a. DNA Cell Biol, 38(3):236-242.

[82]Zhang Y, Xiang C, Wang YL, et al., 2017. LncRNA LINC00152 knockdown had effects to suppress biological activity of lung cancer via EGFR/PI3K/AKT pathway. Biomed Pharmacother, 94:644-651.

[83]Zhang YH, Fu J, Zhang ZJ, et al., 2016. LncRNA-LINC00152 down-regulated by miR-376c-3p restricts viability and promotes apoptosis of colorectal cancer cells. Am J Transl Res, 8(12):5286-5297.

[84]Zhao B, Xu H, Ai X, et al., 2018. Expression profiles of long noncoding RNAs in lung adenocarcinoma. OncoTargets Ther, 11:5383-5390.

[85]Zhao J, Liu YC, Zhang WH, et al., 2015. Long non-coding RNA Linc00152 is involved in cell cycle arrest, apoptosis, epithelial to mesenchymal transition, cell migration and invasion in gastric cancer. Cell Cycle, 14(19):3112-3123.

[86]Zheng LL, Hu N, Zhou XZ, 2019. TCF3-activated LINC00152 exerts oncogenic role in osteosarcoma through regulating miR-1182/CDK14 axis. Pathol Res Pract, 215(2):373-380.

[87]Zhou JP, Zhi XF, Wang LJ, et al., 2015. Linc00152 promotes proliferation in gastric cancer through the EGFR-dependent pathway. J Exp Clin Cancer Res, 34(1):135.

[88]Zhu ZK, Dai JH, Liao YF, et al., 2018. Knockdown of long noncoding RNA LINC00152 suppresses cellular proliferation and invasion in glioma cells by regulating miR-4775. Oncol Res, 26(6):857-867.